Clinical Trial

A Trial to Evaluate the Safety and Immune Response of an Investigational Pneumococcal Vaccine in Adults 50 To 64 Years of Age

Completed Phase 1
View on ClinicalTrials.gov →
Summary
This clinical study is designed to evaluate an investigational pneumococcal vaccine named Pn-MAPS30plus. The vaccine is designed to stimulate the immune system to produce antibodies against various serotypes of the S. pneumoniae bacteria, potentially aiding the body in fighting infection upon exposure. Pn-MAPS30plus aims to broaden protection by covering more serotypes than currently licensed pneumococcal vaccines. The study's purpose is to determine whether the vaccine is safe, well-tolerated, and effective in inducing immune responses against S. pneumoniae.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2025-08-04; most recent amendment 2026-06-04.
Status change: Active, Not Recruiting → Completed 2026-06-04
Status change: Recruiting → Active, Not Recruiting 2025-12-18
Status change: Not Yet Recruiting → Recruiting 2025-08-25
Trial Details
NCT Number NCT07105722
Lead Sponsor GlaxoSmithKline
Conditions Pneumonia, Bacterial
Enrollment 127 participants
Start Date 2025-08-12
Primary Completion 2026-05-06 (estimated)
Study Completion 2026-05-06 (estimated)
Updated on ClinicalTrials.gov 2026-06-05